  Alzheimer's disease (AD) has emerged as a progressively pervasive
neurodegenerative disorder worldwide. Bile acids, synthesized in the liver and
modified by the gut microbiota, play pivotal roles in diverse physiological
processes, and their dysregulation in individuals with AD has been
well-documented. However, the protein targets associated with
microbiota-derived bile acids in AD have received limited attention. To address
this gap, we conducted comprehensive thermal proteomic analyses to unravel and
comprehend the protein targets affected by microbiota-derived bile acids in AD.
Our investigation identified sixty-five unique proteins as potential targets of
deoxycholic acid (DCA), a primary component of the bile acid pool originating
from the gut microbiota. Particularly noteworthy among these proteins were
Nicastrin and Casein kinase 1 epsilon. We found that DCA, through its
interaction with the Nicastrin subunit of {\gamma}-secretase, significantly
contributed to the formation of amyloid beta, a key hallmark of AD pathology.
Additionally, We observed substantial elevations in the urine levels of four
bile acids (DCA, GHCA, GHDCA, and GUDCA) in AD patients compared to healthy
controls. Moreover, the ratios of DCA to cholic acid (CA) and glycodeoxycholic
acid (GDCA) to DCA were significantly increased in AD patients, indicating
aberrations in the biosynthetic pathway responsible for bile acid
dehydroxylation. The augmented levels of microbiota-derived bile acids and
their altered ratios to primary bile acids exhibited notable associations with
AD. Collectively, our findings provide crucial insights into the intricate
interplay between microbiota-derived bile acids and the pathogenesis of AD,
thereby shedding light on potential therapeutic targets for this debilitating
disease.
